Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A

Seeking Alpha14:03 ET

These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird

Seeking AlphaJul 12 14:30 ET

Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255

Morgan Stanley analyst Michael Ulz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and raises the price target from $250 to $255.

BenzingaJul 12 13:16 ET

Alnylam Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 -3.25% Morgan Stanley $250 → $255 Maintains Equal-Weight 07/08/2024 35.45% Canaccord Genuity $2

BenzingaJul 12 13:15 ET

These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey

Seeking AlphaJul 12 10:50 ET

Dividend Roundup: Procter & Gamble, Costco, CVS Health, Colgate-Palmolive, and More

Seeking AlphaJul 12 08:13 ET